The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )
Condition(s) studied
Investigational drug(s) / intervention(s)
Oxytocin lower does (24IU): Oxytocin (24IU) will be administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue)
Oxytocin higher does (48IU): Oxytocin (48IU) will be administered as a lingual spray (6, 0.1ml sprays (8IU per puff) on and under the tongue)
Atosiban: 150ug atosiban administered by lingual sprays (6, 0.1ml sprays on and under the tongue)
Placebo: Placebo administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue). Placebo has the same composition of 0.9% saline and glycerol as for oxytocin and the atosiban interventions.
Study summary
The main aim of the present study is to investigate whether orally (lingual spray) administered oxytocin influences human top-down attention via oxytocin receptors and whether its effects are dose- and task-dependent.
Eligibility
Primary outcome measure(s)
- Error rates in prosaccade and antisaccade trials — Starting 45 minutes post-treatment subjects will complete the eye-tracking task with data on numbers of prosaccade and antisaccade errors being collected continuously over a period of 35 minutes.
Error rates in prosaccade and antisaccade using eye- tracking technique - Responses latencies for prosaccades and antisaccades — Starting 45 minutes post-treatment subjects will complete the eye-tracking task with data on prosaccade and antisaccade response times taken continuously during the 35 minute task
response latencies for correct first saccades will be measured on each prosaccade or antisaccade trial using eye-tracking
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| School of Life science and Technology, University of Electronic Science and Technology of China | Chengdu | Sichuan | Recruiting |
More University of Electronic Science and Technology of China trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07140237 on ClinicalTrials.gov ↗ ← All trials in China